Healthcare Industry News: Cook
News Release - November 15, 2006
Merck Wins Federal VIOXX(R) Product Liability CaseMason v. Merck & Co.
WHITEHOUSE STATION, N.J.--(HSMN NewsFeed)--Merck & Co., Inc. today said it is pleased that a federal court jury in New Orleans found in favor of Merck, rejecting a claim that VIOXX caused the 2003 heart attack of a then 61-year-old Utah man.
In the case, Charles Laron Mason claimed he took VIOXX for approximately 10 months before his heart attack. The Mason case was specifically selected by the Plaintiffs' Steering Committee for this trial.
"The jury determined that Merck acted appropriately in the development and marketing of VIOXX and that VIOXX did not substantially contribute to Mr. Mason's heart attack," said Phil Beck, of the law firm of Bartlit Beck, Merck's lead trial lawyer in the case, Mason v. Merck.
"In addition, Mr. Mason's claims about his VIOXX use simply didn't hold up to scrutiny," Beck said. "On the witness stand, Mr. Mason reversed his previous testimony and admitted - for the first time - that he was not even taking VIOXX in the days before his heart attack. He also had multiple risk factors for a heart attack including significant coronary artery disease, a family history of cardiac problems and he was considered medically obese," Beck said. "Unfortunately, Mr. Mason would have suffered a heart attack whether he was taking VIOXX or not."
Merck has now won three out of the four federal VIOXX cases to go to trial.
"This is a satisfying verdict for Merck," said Kenneth C. Frazier, executive vice president and general counsel of Merck. "Juries across the country, in both state and federal courts, have determined that the Company acted responsibly in properly disclosing data to the medical community."
U.S. District Court Judge Eldon E. Fallon of the Eastern District of Louisiana, who is overseeing all of the federal court VIOXX litigation, presided over the case. The lawsuit was filed in the Multi-District Litigation as case number 06-00810 in 2006.
"Heart attacks are, unfortunately, a leading cause of death in the United States and have multiple causes," said Mr. Frazier. "Plaintiffs have the burden of proving their claims and that is why we are addressing these cases on an individual basis. Our strategy has now resulted in seven favorable jury verdicts, including four of the last five cases, and more than 3,000 case dismissals."
Merck was represented in the Mason case by Phil Beck, Tarek Ismail and Shayna Cook of Bartlit Beck Herman Palenchar & Scott LLP of Chicago. Bartlit Beck also was the lead counsel in the previous federal VIOXX cases.
Of the 16 cases that have now been scheduled for trial and are no longer pending, only four have resulted in a plaintiff's verdict. Juries have decided in Merck's favor in seven cases and five cases have been dismissed.
Another five cases, previously scheduled for trial, have been withdrawn from the trial calendar by the plaintiffs before the claims could reach trial.
As for the four plaintiff's verdicts, Merck already has filed an appeal or sought judicial review in each of those cases, and in one of those four, a federal judge overturned the damage award shortly after trial. Additionally, a state judge set aside one of the seven Merck verdicts.
Finally, the claims of more than 3,000 plaintiff groups, not yet scheduled for trial, have been dismissed. That includes more than 1,100 plaintiff groups whose claims were dismissed with prejudice either by plaintiffs themselves or by the courts, meaning they cannot be filed again. More than 2,000 additional plaintiff groups have had their claims dismissed without prejudice.
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMerck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Endo Launches Authorized Generic Version of Noxafil(R) (posaconazole) Delayed-release Tablets in the United States
Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA(R) (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer